A trial to determine if daily topical applications of becaplermin gel is successful in treating patients with pressure ulcers. Topical becaplermin has been shown to have significant effects on wound healing in mice, rats, guinea pigs, and domestic pigs. The usual action of becaplermin in these animal models is to promote the formation of granulation tissue in the wound. The toxicology of becaplermin has been evaluated in the mouse, rat, rabit, guinea pig, dog, and monkey. The results of these studies indicate that becaplermin has minimal toxicity intravenously, under the skin, and on top of the skin. Preclinical and clinical studies indicate that becaplermin gel is safe and effective in the treatment of diabetic ulcers. Studies in patients with full thickness diabetic ulcers showed negligible absorption. The clinical assessment of absorption in subjects with pressure ulcers has only been conducted with 30 ug/g gel formation. This study will further evaluate the extent of systematic absorption of becaplermin from a topically applied 100 ug/g gel formation in subjects with pressure ulcers using state-of-the-art analytical and sample preparation techniques. At least twelve subjects will be studied. Subjects must have full thickness pressure ulcers, not be pregnant, must have ulcers free of joint capsule or bone exposure, must have ulcers that are free of narcotic and infected soft tissue, negative hepatitis B tests, must not comsume alcohol for 48 hours prior to the study and until the end of the study, and must give written, informed consent. Following a screening period, during which subjects will have serial blood samples collected at specific times to establish baseline fluid growth concentrations of PDGF-BB, subjects will apply becaplermin gel 100ug/g once daily for two weeks. Subjects will be confined for 24 hours for collection of serial blood samples on days 1 and 14 of the therapy. Prior to study drug administration on days 1 and 14, a serum collection for anti-PDGF antibody will occur. Final study procedures will be performed on day 15.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-38
Application #
6419277
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
38
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8

Showing the most recent 10 out of 367 publications